Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of SCLC.
• First recurrence of SCLC after therapy with one prior chemotherapy regimen at initial diagnosis.
• Relapsed SCLC of any duration (both sensitive and resistant relapse).
• ECOG performance status of </= 2.
• Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.
• No prior therapy with bevacizumab or any other VEGF inhibitor or topotecan

Exclusion Criteria:

• Uncontrolled emesis, regardless of etiology.
• Active uncontrolled infection.
• GI conditions or drugs that could impact absorption of oral topotecan.
• Known hypersensitivity to any component of topotecan capsule or compounds chemically related to topotecan.
• Uncontrolled hypertension with BP>150/100.
• Prior h/o hypertensive crisis or encephalopathy.
• NYHA Grade II or greater congestive heart failure.
• H/O myocardial infarction within 6 months.
• H/O stroke or TIA within 6 months.
• H/O thrombotic or hemorrhagic disorders.
• Clinically significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.
• Anticipation of need for major surgical procedure during the study.
• Minor surgical procedures within 7 days prior to treatment start (placement of vascular access devices is permitted).
• H/O abdominal fistula, GI perforation, or intra-abdominal abscess within prior 6 months. Serious, non-healing wound, active ulcer, or untreated bone fracture. - H/O hemoptysis within prior 1 month.
• Concurrent radiotherapy.
• H/O whole lung radiation within 90 days prior to start of treatment.
• Presence or h/o central nervous system or brain metastases.
• H/o another malignancy other than SCLC.
• Concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment of small cell lung cancer.